Abstract 1580
Background
Brain metastases (BMs) account for a relatively large proportion of patients with metastatic non-small cell lung cancer (NSCLC) both at the time of diagnosis and during the course of disease, which is a major cause leading to a significant increase in cancer-related mortality for NSCLC patients. We aimed to build a novel risk classification system to predict overall survival (OS) of patients presenting with BMs at the first diagnosis of NSCLC.
Methods
Data on NSCLC patients with BMs was extracted from the SEER database between 2010 and 2013. All cases were randomly divided into the training cohort and validation cohort (7:3). Cox regression was performed to select the independent predictors of OS. A nomogram was established for predicting 6-, 12- and 18-month OS. The prognostic performance of nomogram was evaluated using concordance indexes (C-indexes), calibration curves, and decision curve analyses (DCAs). All statistical analysis was performed with R software.
Results
According to the multivariate Cox regression of the training set, the following variables were contained in the nomogram prognostic model: age, marital status, sex, race, primary site, histological type, T stage, N stage, metastatic pattern, whether received radiotherapy and chemotherapy. The nomogram displayed good accuracy in predicting 6, 12 and 18 months OS. The C-indexes of training set and validation set were 0.729 and 0.723, respectively. The calibration curves showed excellent consistency between the actual results and the nomogram prediction, and the DCAs exhibited great clinical utility of the model. A new risk classification system based on nomogram scores was introduced to classify NSCLC patients with BMs into three subgroups. In the training cohort, the median OS of patients in the low-, intermediate- and high-risk groups was 11.0 months (95% confidence interval [CI] 10.3–11.7), 5.0 months (95% CI 4.6–5.4), and 2.0 months (95% CI 1.9–2.1), respectively.
Conclusions
We established a risk stratification system based on nomogram scores to predict the OS of patients presenting with BMs at initial diagnosis of NSCLC. These predictive models can act as auxiliary tools to guide treatment strategies and prognostic evaluation.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4242 - HIV, HBV and HCV screening practices in oncology: a cross-sectional interregional survey
Presenter: Isabelle Poizot-Martin
Session: Poster Display session 1
Resources:
Abstract
1267 - Genetic landscape of KEAP1 and NFE2L2 mutated cancers from the AACR GENIE database
Presenter: Mark Zaki
Session: Poster Display session 1
Resources:
Abstract
878 - β-arrestin1 is involved in the Ras-induced malignant transformation
Presenter: Takashi Shibano
Session: Poster Display session 1
Resources:
Abstract
4143 - Incidence of second cancer among PLWHIV: retrospective observational study of a series of 601 patients in the French CANCERVIH network
Presenter: Jean-Philippe Spano
Session: Poster Display session 1
Resources:
Abstract
5145 - A challenging task – Identifying carcinoma of unknown primary (CUP) patients according to ESMO guidelines: the CUPISCO trial experience
Presenter: Chantal Pauli
Session: Poster Display session 1
Resources:
Abstract
1737 - Incidence and Outcome of chronic lymphocytic leukemia with Deletion 17p: An Indian experience; challenges and opportunities
Presenter: Ajay Gogia
Session: Poster Display session 1
Resources:
Abstract
2596 - Driving solo? Investigation into collaborating mutations in SDH-deficient neoplasia
Presenter: Jonathan Killian
Session: Poster Display session 1
Resources:
Abstract
1499 - The potential of a novel antiangiogenic VEGFR1-D2 binding peptide in oncology therapeutics
Presenter: Afsaneh Sadre Momtaz
Session: Poster Display session 1
Resources:
Abstract
1775 - First-in-human phase I study of TAS-117, an allosteric AKT inhibitor, in patients with advanced solid tumors
Presenter: Mayu Yunokawa
Session: Poster Display session 1
Resources:
Abstract
4584 - First-in-human study of ABBV-621 in patients (pts) with previously treated sold tumors: Dose-optimization cohorts
Presenter: Emiliano Calvo
Session: Poster Display session 1
Resources:
Abstract